We Believe Longevity & Wellness is the Future
Vesalius Longevity Labs is building a leading global peptide brand backed by science and quality.
Peptides are one of the fastest-moving areas in longevity, and Vesalius is building the whole path from lab to consumer. That means Made-in-the-USA peptide APIs under its Peptual® brand, a doctor-led model that connects licensed providers and AI-powered tools for more personalized care that connect providers to pharmacies.
Why Invest?
-
Massive and expanding market. The global peptide therapeutics market is projected to grow from about US$141 billion in 2025 to US$295 billion by 2033.² This sits within a global wellness economy of US$6.8 trillion, with 7.3% projected average annual growth from 2023 to 2028.¹
-
Exclusive manufacturing agreement with Celularity (NASDAQ: CELU). U.S.-based final-stage active pharmaceutical ingredient (API) manufacturing and supply platform for Vesalius's Peptual® peptide products. Supplied to licensed U.S. and international 503A compounding pharmacies.
-
Scalable revenue model with multiple growth engines. 5 key revenue streams: Peptual® peptide portfolio, pens, telemedicine, API production and MCI collaboration
-
Global platform. Provider network across the U.S., EU and UAE, with Mexico pending regulatory approval
-
Recurring healthcare and wellness revenue. Revenue comes from the Peptual® peptide portfolio, telemedicine, and the collaboration with MuseCell Innovations (Peptual Skin, Dezawa Aesthetics™ and Dezawa MuseCell®).
-
Strong leadership and advisory team. The board, scientific advisors and management bring experience across healthcare, biotech, fintech, consumer platforms and public markets.
1 Global Wellness Institute, Global Wellness Economy Monitor 2024 (Nov. 2024): US$6.8 trillion in 2023; 7.3% projected average annual growth, 2023–2028.
² Grand View Research, Peptide Therapeutics Market Size, Share & Trends Analysis Report, 2026–2033 (2026): US$140.9B in 2025; US$294.6B by 2033; 8.73% CAGR, 2026–2033.
Third-party data has not been independently verified by the Company